Cargando…

Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation

AIMS: Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in the atrial myocardium. We evaluated the associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijazi, Ziad, Benz, Alexander P, Lindbäck, Johan, Alexander, John H, Connolly, Stuart J, Eikelboom, John W, Granger, Christopher B, Kastner, Peter, Lopes, Renato D, Ziegler, André, Oldgren, Jonas, Siegbahn, Agneta, Wallentin, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839419/
https://www.ncbi.nlm.nih.gov/pubmed/36380569
http://dx.doi.org/10.1093/eurheartj/ehac632
_version_ 1784869480663351296
author Hijazi, Ziad
Benz, Alexander P
Lindbäck, Johan
Alexander, John H
Connolly, Stuart J
Eikelboom, John W
Granger, Christopher B
Kastner, Peter
Lopes, Renato D
Ziegler, André
Oldgren, Jonas
Siegbahn, Agneta
Wallentin, Lars
author_facet Hijazi, Ziad
Benz, Alexander P
Lindbäck, Johan
Alexander, John H
Connolly, Stuart J
Eikelboom, John W
Granger, Christopher B
Kastner, Peter
Lopes, Renato D
Ziegler, André
Oldgren, Jonas
Siegbahn, Agneta
Wallentin, Lars
author_sort Hijazi, Ziad
collection PubMed
description AIMS: Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in the atrial myocardium. We evaluated the association between BMP10 and the risk of ischaemic stroke and other cardiovascular events in large cohorts of patients with AF, treated with and without oral anticoagulation (OAC). METHODS AND RESULTS: BMP10 was measured in plasma samples collected at randomisation in patients with AF without OAC in the ACTIVE A and AVERROES trials (n = 2974), and with OAC in the ARISTOTLE trial (n = 13 079). BMP10 was analysed with a prototype Elecsys immunoassay. Associations with outcomes were evaluated by Cox-regression models adjusted for clinical characteristics, kidney function, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Median concentrations of BMP10 were 2.47 and 2.44 ng/mL, in the non-OAC and OAC cohort, respectively. Increasing BMP10 was associated with lower body mass index, older age, female sex, kidney dysfunction, and AF rhythm. BMP10 was consistently associated with ischaemic stroke. In the non-OAC cohort, BMP10 increased the concordance index of the multivariable model from 0.713 to 0.733 (P = 0.004) and in the OAC cohort from 0.673 to 0.694 (P < 0.001). Additionally, BMP10 maintained a significant prognostic value after additionally adjusting for NT-proBNP. BMP10 was not independently associated with bleeding or with death. CONCLUSION: The novel atrial biomarker BMP10 was independently associated with ischaemic stroke in patients with AF irrespective of OAC treatment. BMP10 seems to be more specifically related to the risk of ischaemic stroke in AF. ONE-SENTENCE SUMMARY: In this study, BMP10 may be a novel specific biomarker of ischaemic stroke in patients with atrial fibrillation, irrespective of oral anticoagulation.
format Online
Article
Text
id pubmed-9839419
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98394192023-01-17 Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation Hijazi, Ziad Benz, Alexander P Lindbäck, Johan Alexander, John H Connolly, Stuart J Eikelboom, John W Granger, Christopher B Kastner, Peter Lopes, Renato D Ziegler, André Oldgren, Jonas Siegbahn, Agneta Wallentin, Lars Eur Heart J Clinical Research AIMS: Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in the atrial myocardium. We evaluated the association between BMP10 and the risk of ischaemic stroke and other cardiovascular events in large cohorts of patients with AF, treated with and without oral anticoagulation (OAC). METHODS AND RESULTS: BMP10 was measured in plasma samples collected at randomisation in patients with AF without OAC in the ACTIVE A and AVERROES trials (n = 2974), and with OAC in the ARISTOTLE trial (n = 13 079). BMP10 was analysed with a prototype Elecsys immunoassay. Associations with outcomes were evaluated by Cox-regression models adjusted for clinical characteristics, kidney function, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Median concentrations of BMP10 were 2.47 and 2.44 ng/mL, in the non-OAC and OAC cohort, respectively. Increasing BMP10 was associated with lower body mass index, older age, female sex, kidney dysfunction, and AF rhythm. BMP10 was consistently associated with ischaemic stroke. In the non-OAC cohort, BMP10 increased the concordance index of the multivariable model from 0.713 to 0.733 (P = 0.004) and in the OAC cohort from 0.673 to 0.694 (P < 0.001). Additionally, BMP10 maintained a significant prognostic value after additionally adjusting for NT-proBNP. BMP10 was not independently associated with bleeding or with death. CONCLUSION: The novel atrial biomarker BMP10 was independently associated with ischaemic stroke in patients with AF irrespective of OAC treatment. BMP10 seems to be more specifically related to the risk of ischaemic stroke in AF. ONE-SENTENCE SUMMARY: In this study, BMP10 may be a novel specific biomarker of ischaemic stroke in patients with atrial fibrillation, irrespective of oral anticoagulation. Oxford University Press 2022-11-16 /pmc/articles/PMC9839419/ /pubmed/36380569 http://dx.doi.org/10.1093/eurheartj/ehac632 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
Hijazi, Ziad
Benz, Alexander P
Lindbäck, Johan
Alexander, John H
Connolly, Stuart J
Eikelboom, John W
Granger, Christopher B
Kastner, Peter
Lopes, Renato D
Ziegler, André
Oldgren, Jonas
Siegbahn, Agneta
Wallentin, Lars
Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
title Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
title_full Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
title_fullStr Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
title_full_unstemmed Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
title_short Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
title_sort bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9839419/
https://www.ncbi.nlm.nih.gov/pubmed/36380569
http://dx.doi.org/10.1093/eurheartj/ehac632
work_keys_str_mv AT hijaziziad bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT benzalexanderp bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT lindbackjohan bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT alexanderjohnh bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT connollystuartj bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT eikelboomjohnw bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT grangerchristopherb bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT kastnerpeter bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT lopesrenatod bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT zieglerandre bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT oldgrenjonas bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT siegbahnagneta bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation
AT wallentinlars bonemorphogeneticprotein10anovelriskmarkerofischaemicstrokeinpatientswithatrialfibrillation